While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Effective immediately, only two people are permitted at the bedside of patients during the day and one person overnight at ...

The Health Protection Surveillance Centre (HPSC) has reported a further reduction in cases of flu, the Respiratory Syncytial ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

The Cyprus pulmonology society on Thursday urged Health Minister Michael Damianos to approve a respiratory syncytial virus ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

RSV and whooping cough are all on the decline in Minnesota. The bad news? Norovirus case counts have climbed this month, and ...

Wales is past the peak of its flu season according to public health bosses. Cases of flu have caused chaos in Wales' ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

The UKHSA is behind the new warning as a raft of illnesses, including flu, COVID, RSV, norovirus and hMPV, spread across the ...